Cumberland Pharmaceuticals (CPIX) Return on Capital Employed (2011 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Return on Capital Employed of 18.3% for Q1 2026, down 1137.0% on a YoY basis from 1.76% in Q1 2025, and down 126.86% sequentially from 8.07% in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 16 years of Return on Capital Employed data on file, last reported at 18.3% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1137.0% year-over-year to 18.3%; the trailing twelve-month figure through Mar 2026 stood at 18.3% (down 1137.0% YoY), and the FY2025 full-year result was 7.08%, up 659.0% from the prior year.
- Return on Capital Employed fell to 18.3% in Q1 2026, from 8.07% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 6.52% in Q2 2023 to a low of 23.14% in Q3 2024.
- A 5-year average of 12.43% and a median of 11.73% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 1391 bps in 2024 and jumped 1548 bps in 2025, its largest moves.
- Tracing CPIX's Return on Capital Employed over 5 years: stood at 9.02% in 2022, then slumped by 87 bps to 16.83% in 2023, then rose by 14 bps to 14.44% in 2024, then surged by 44 bps to 8.07% in 2025, then sank by 127 bps to 18.3% in 2026.
- Business Quant data shows CPIX's Return on Capital Employed at 18.3% in Q1 2026, 8.07% in Q4 2025, and 7.66% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn | -18.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.30% |
| Dec 31, 2025 | -8.07% |
| Sep 30, 2025 | -7.66% |
| Jun 30, 2025 | -6.66% |
| Mar 31, 2025 | -6.92% |
| Dec 31, 2024 | -14.44% |
| Sep 30, 2024 | -23.14% |
| Jun 30, 2024 | -19.80% |
| Mar 31, 2024 | -17.92% |
| Dec 31, 2023 | -16.83% |
| Sep 30, 2023 | -9.23% |
| Jun 30, 2023 | -6.52% |
| Mar 31, 2023 | -9.08% |
| Dec 31, 2022 | -9.02% |
| Sep 30, 2022 | -11.73% |
| Jun 30, 2022 | -12.87% |
| Mar 31, 2022 | -13.09% |
| Dec 31, 2021 | -11.50% |
| Sep 30, 2021 | -7.21% |
| Jun 30, 2021 | -6.51% |